Navigation Links
BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
Date:1/7/2009

SAN ANTONIO, Jan. 7 /PRNewswire/ -- BioMedical Enterprises, Inc. (BME), a cutting edge medical device company focused on the development of orthopaedic memory metal implants, announced today that it has appointed Kenneth I. Moch as its President and Chief Executive Officer. W. Casey Fox, PhD, P.E., BME's Founder, will become Chief Technology Officer and continue to focus his efforts on building BME's innovative product offerings.

BME specializes in nitinol implants that contract and compress bone after implantation, bringing bone ends together to promote bone union. These proprietary implants allow the surgeon to finely control the amount of compression and rate of force application generated on bones, thereby reducing fractures and stimulating bone healing.

"Ken is a proven leader who brings extensive senior management and operational experience to BME, as well as a shared strategic vision to create a leading medical device company," said Richard M. Johnston, Chairman of BME and Managing Member of Camden Partners Holdings, LLC.

Mr. Moch has served as the President of Euclidean Life Science Advisors, which provides strategic advisory services to life sciences companies, since early 2008. He previously was Managing Director, Healthcare Investment Banking at ThinkEquity Partners and Chairman, President and CEO of Alteon, Inc., a biotech company specializing in small molecule therapeutics for cardiovascular aging and diabetic complications. Mr. Moch earlier served as President and CEO of Biocyte Corporation, the cellular therapy company that pioneered the collection and commercial application of cord blood stem cells, and as a management consultant with McKinsey & Company, Inc. Mr. Moch holds a degree in biochemistry from Princeton University and an MBA from the Stanford Graduate School of Business.

"It is a privilege to be joining BME at this exciting time in the company's history," said Mr. Moch. "I believe that BME's unique technology and innovative products have tremendous commercial growth potential. Together with BME's talented employees, I look forward to accelerating the growth of the Company and broadening the use of our novel memory metal implants."

"Ken's involvement is a statement to our distributor partners that we intend to grow our business for our mutual benefit. With in-house manufacturing now on line at BME we have the capability, support and focus for new product development and the continued improvement of our product lines," said Casey Fox, PhD.

About BioMedical Enterprises, Inc.

BME designs, manufactures and markets memory metal implants used in orthopaedic reconstructive surgery and fracture management. BME's patented implant system utilizes the unique properties of the shape memory alloy nitinol to provide controlled long-term compression that enhances the body's natural healing process in an effort to achieve faster healing times and fewer complications. BME's barbed and smooth OSStaple(TM) lines of bone fusion implants, part of the OSSforce(TM) fixation system, are designed to achieve controlled long-term compression of bone fragments. BME's OSSAnchor(TM) line of soft tissue fixation implants give surgeons a simple yet powerful tool to attach soft tissue to bone.

For more information about BME and its unique products visit http://www.bme-tx.com.


'/>"/>
SOURCE BioMedical Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
2. Response Biomedical Corporation Announces Change of Executives
3. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
4. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
5. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
6. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
7. Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
8. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
9. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
10. Interview with Dr. Elisabeth Hager, CEO of Balan Biomedical, Inc., to Air Nationally on Sky Radio
11. Response Biomedical Closes $5.1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: A Story ... parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of Love” is ... Island, New York. , Published by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s ...
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, 2017 — ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , According ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, ... new charity drive to generate community support for efforts to educate the local population ... treatments for all types of cancer. , Each day in America, roughly 4,600 ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
Breaking Medicine Technology: